-
Current Allergy and Asthma Reports Mar 2016PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions... (Review)
Review
PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions are rare but increasingly recognized adverse effects of proton pump inhibitors (PPIs). Immediate hypersensitivity reactions can occur due to IgE-mediated hypersensitivity to PPIs and can be evaluated by immediate hypersensitivity skin testing and oral provocation challenge testing. A desensitization protocol can be used when PPI use cannot be avoided in an allergic patient. Delayed hypersensitivity reactions to PPIs have also been reported. Occupational exposures causing cutaneous reactions to PPIs are the most commonly reported delayed hypersensitivity reaction, followed by drug-induced subacute cutaneous lupus erythematosus. This review presents a summary of the clinical presentation, diagnostic evaluation, and management of immune-mediated hypersensitivity reactions to PPIs.
Topics: Animals; Drug Hypersensitivity; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Lupus Erythematosus, Cutaneous; Proton Pump Inhibitors; Skin Tests
PubMed: 26810177
DOI: 10.1007/s11882-016-0595-8 -
The Oncologist May 2007Like nearly all systemic cancer therapies, monoclonal antibodies are associated with hypersensitivity reactions. This article reviews the characteristics and management... (Review)
Review
BACKGROUND
Like nearly all systemic cancer therapies, monoclonal antibodies are associated with hypersensitivity reactions. This article reviews the characteristics and management of hypersensitivity reactions to monoclonal antibodies and commonly used chemotherapy agents.
METHODS
MEDLINE was searched for recent studies and reviews pertaining to hypersensitivity reactions with monoclonal antibodies (cetuximab, rituximab, trastuzumab, panitumumab, bevacizumab), platinum compounds (carboplatin, oxaliplatin), and taxanes (paclitaxel, docetaxel). Emphasis was placed on articles that provided practical information on hypersensitivity reaction management. Data found in the literature were supplemented with information from the package insert for each agent.
RESULTS
Severe hypersensitivity reactions are rare, with an incidence of < or =5%, provided patients receive proper premedication, close monitoring, and prompt intervention when symptoms occur. Hypersensitivity reactions to platinum compounds are generally consistent with type 1 hypersensitivity, occurring after multiple cycles of therapy. Reactions to taxanes and monoclonal antibodies produce similar symptoms, but are generally immediate, occurring during the first few minutes of the first or second infusion. However, 10%-30% of reactions to monoclonal antibodies are delayed, and may occur in later infusions, indicating the importance of close observation of the patient following administration. Mild-to-moderate reactions can be managed by temporary infusion interruption, reduction of the infusion rate, and symptom management. Rechallenge should be considered after complete resolution of all symptoms. Severe reactions may require treatment discontinuation.
CONCLUSION
Hypersensitivity or infusion reactions to platinum compounds are acquired; reactions to taxanes and monoclonal antibodies are immediate and typically occur during the first few minutes of the first infusion. The different time of onset should be considered when developing strategies for preventing and managing hypersensitivity reactions. The decision to rechallenge or discontinue treatment after a reaction occurs depends on the severity of the reaction and other clinical factors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Drug Hypersensitivity; Humans; Hypersensitivity, Delayed; Immunologic Factors; Incidence; Infusions, Intravenous; Platinum Compounds; Taxoids; Time Factors
PubMed: 17522249
DOI: 10.1634/theoncologist.12-5-601 -
Journal Der Deutschen Dermatologischen... Nov 2011Corticosteroids are therapeutic agents used in cases of allergy and intolerance. Due to the antiinflammatory effects of the corticosteroids, hypersensitivity reactions... (Review)
Review
Corticosteroids are therapeutic agents used in cases of allergy and intolerance. Due to the antiinflammatory effects of the corticosteroids, hypersensitivity reactions often are considered to be a paradox. However, delayed-type reaction to corticosteroids is a frequent phenomenon in the daily routine. Non-responding eczema, development of subacute contact eczema, systemic contact dermatitis or maculopapular exanthemas can be a clinical symptom of a delayed-type hypersensitivity reaction to corticosteroids. Immediate-type hypersensitivity reactions to corticosteroids remain uncommon. Nevertheless, they can take a severe clinical course. Patients react with anaphylaxis after systemic administration or with aggravation of an allergic reaction under therapy with corticosteroids. Allergologic testing is necessary for diagnosis and providing alternative corticosteroids in case of an emergency.
Topics: Adrenal Cortex Hormones; Anaphylaxis; Drug Eruptions; Humans; Hypersensitivity, Delayed; Hypersensitivity, Immediate; Intradermal Tests; Patch Tests; Structure-Activity Relationship
PubMed: 21718445
DOI: 10.1111/j.1610-0387.2011.07718.x -
Journal of the European Academy of... Sep 2022
Topics: Drug Hypersensitivity; Humans; Hyaluronoglucosaminidase; Hypersensitivity; Hypersensitivity, Delayed
PubMed: 35398928
DOI: 10.1111/jdv.18133 -
Science Progress 1971
Review
Topics: Allergens; Anaphylaxis; Animals; Antibody Formation; Antigen-Antibody Reactions; Antigens, Bacterial; Autoimmune Diseases; Cell Membrane Permeability; Cell Migration Inhibition; Dermatitis, Contact; Dogs; Guinea Pigs; Histamine H1 Antagonists; Histamine Release; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Lymph Nodes; Passive Cutaneous Anaphylaxis; RNA; Rats; Transplantation Immunology; Tuberculin
PubMed: 4107783
DOI: No ID Found -
Microscopy Research and Technique May 2001Cell-mediated immunity is defined as a beneficial host response characterized by an expanded population of specific T cells, which, in the presence of antigens, produce... (Review)
Review
Cell-mediated immunity is defined as a beneficial host response characterized by an expanded population of specific T cells, which, in the presence of antigens, produce cytokines locally. The activation and recruitment of cells into an area of inflammation is a crucial step in the development of DTH responses. DTH is immunologically a process similar to cell-mediated immunity, involving T cells and cytokines. CD4 T helper (Th) 1 cells, differentiated from naive Th cells by IL-12 and IL-18 produced from macrophages, play a regulatory role in the expression of DTH and activation of macrophages via interferon gamma generated by Th1 and natural killer cells. Macrophages accumulate at the site of DTH and become activated through the CD4 Th1 cell-cytokine-macrophage axis. However, DTH leads to pathologic responses, such as granulomatous inflammation, calcification, caseation necrosis, and cavity formation. Granulomas usually form as a result of the persistence of a nondegradable product or as the result of DTH responses. DTH is also required for host defense against etiologic agents, such as Mycobacterium tuberculosis. The expression of cell-mediated immunity/DTH is a double-edged sword that may contribute to both clearance of the etiologic agent and tissue damage.
Topics: Antibodies; Granuloma; Humans; Hypersensitivity, Delayed; Immunity, Cellular; Mycobacterium avium-intracellulare Infection
PubMed: 11340669
DOI: 10.1002/jemt.1090 -
Lancet (London, England) May 1967
Topics: Antibodies; Antigens; Humans; Hypersensitivity, Delayed; Lymphocytes
PubMed: 4164612
DOI: No ID Found -
International Journal of Dermatology Jun 2024
Topics: Humans; Hypersensitivity, Delayed; Animals; Female; Scyphozoa; Male; Cnidarian Venoms
PubMed: 38415851
DOI: 10.1111/ijd.17110 -
Methods in Molecular Biology (Clifton,... 2012Delayed-type hypersensitivity responses in the skin (in the case of mice, in the foot pad) is used to assess cell-mediated immunity (CMI) in vivo. In the case of CMI to...
Delayed-type hypersensitivity responses in the skin (in the case of mice, in the foot pad) is used to assess cell-mediated immunity (CMI) in vivo. In the case of CMI to Helicobacter infection, the mice are given an injection of cultured Helicobacter organisms into the hind footpad, and induration is measured at the site of inoculation 24 h after inoculation. Here we describe the methods for assessing delayed-type hypersensitivity in the mouse.
Topics: Animals; Disease Models, Animal; Helicobacter pylori; Hypersensitivity, Delayed; Immunity, Cellular; Mice
PubMed: 23015499
DOI: 10.1007/978-1-62703-005-2_16 -
The Journal of Investigative Dermatology Jul 1978Basophilic leukocytes constitute a significant proportion of the cellular infiltrates in many forms of delayed-in-onset hypersensitivity reactions in human beings,... (Review)
Review
Basophilic leukocytes constitute a significant proportion of the cellular infiltrates in many forms of delayed-in-onset hypersensitivity reactions in human beings, guinea pigs, and other animals. In this paper, I review current information on the role of basophils in the reactions, and present similarities and differences between Jones-Mote and classic delayed hypersensitivities.
Topics: Animals; Antigen-Antibody Reactions; Basophils; Guinea Pigs; Humans; Hypersensitivity, Delayed; Skin; Skin Tests
PubMed: 355569
DOI: 10.1111/1523-1747.ep12544415